LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.48 -5.73

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.44

Max

1.5899999999999999

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+204.49% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	48M 174M
Eelmine avamishind	7.21
Eelmine sulgemishind	1.48

Uudiste sentiment

By Acuity

76%

24%

321 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. veebr 2026, 23:53 UTC

Kuumad aktsiad

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27. veebr 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

27. veebr 2026, 17:55 UTC

Kuumad aktsiad

Toronto Stocks Decline, But Remain On Track for Weekly Gains

27. veebr 2026, 23:46 UTC

Omandamised, ülevõtmised, äriostud

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27. veebr 2026, 23:33 UTC

Omandamised, ülevõtmised, äriostud

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27. veebr 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

27. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27. veebr 2026, 21:30 UTC

Tulu

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27. veebr 2026, 21:30 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27. veebr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27. veebr 2026, 21:17 UTC

Tulu

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27. veebr 2026, 21:10 UTC

Omandamised, ülevõtmised, äriostud

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27. veebr 2026, 21:09 UTC

Omandamised, ülevõtmised, äriostud

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27. veebr 2026, 21:00 UTC

Tulu

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27. veebr 2026, 20:31 UTC

Omandamised, ülevõtmised, äriostud

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27. veebr 2026, 20:24 UTC

Market Talk

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27. veebr 2026, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27. veebr 2026, 20:12 UTC

Market Talk

Nike Seen With Further Challenges in China -- Market Talk

27. veebr 2026, 19:44 UTC

Market Talk

Gold Caps Historic Month -- Market Talk

27. veebr 2026, 19:39 UTC

Tulu

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27. veebr 2026, 19:38 UTC

Tulu

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

27. veebr 2026, 18:53 UTC

Omandamised, ülevõtmised, äriostud

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

27. veebr 2026, 18:45 UTC

Tulu

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

27. veebr 2026, 18:45 UTC

Market Talk

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

27. veebr 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

27. veebr 2026, 17:07 UTC

Tulu

Pemex Cuts 4Q Loss As Operating Results Improve

27. veebr 2026, 17:00 UTC

Market Talk

Corn Rides Oil Momentum Higher -- Market Talk

27. veebr 2026, 16:31 UTC

Market Talk

Canadian Economy Shows Resilience -- Market Talk

27. veebr 2026, 16:17 UTC

Market Talk

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

27. veebr 2026, 15:49 UTC

Tulu

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

204.49% tõus

12 kuu keskmine prognoos

Keskmine 4.75 USD 204.49%

Kõrge 7 USD

Madal 2.5 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

321 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.